---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330644"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-08-03T20:24:23+00:00"
generated_at: "2026-08-03T20:25:06.812680+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+

## Summary
- CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.
- Initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency) using in vivo LNP delivery.
- Cash $2.36B at June 30, 2026, up from $1.98B at Dec 31, 2025, boosted by $585M convertible note issuance.
- Net loss narrowed to $91.2M from $208.5M in Q2 2025, driven by lower acquired IPR&D and higher CASGEVY revenue.
- Phase 1b update for CTX310 (ANGPTL3) expected at ESC Congress Aug 28; Phase 2 for CTX611 (FXI siRNA) ongoing.

## SEC filing metadata
- accession: 0001193125-26-330644
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-08-03T20:24:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/0001193125-26-330644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330644
- JSON: https://secwatch.observer/filing/0001193125-26-330644.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.